GLP-1 is an incretin hormone produced by intestinal L cells and the brain. GLP-1 is released in response to food intake to stimulate glucose-dependent insulin secretion by the pancreas. Additionally, GLP-1 exerts multiple other effects, including inhibition of food intake, slowing gastric emptying, and inhibition of glucagon secretion. Thus, GLP-1 was considered as a good target for the treatment of T2DM. However, therapeutic application of GLP-1 is hampered due to its short circulating half-life (
SGLT-2 Inhibitors have the best cardiovascular outcome data, so I'd say yes, there is something better now.
Thanks, Thomas W Weiss; but I think SGLT-2 inhibitors having contraindication like it increases acid in the blood which leads to ketone bodies formation, patients some time hospitalized in critical condition. Although, FDA approved drug but sorry to say its use unsafe for all....
Yes, we can improve pharmacokinetics for GLP-1 analogues. Human GLP-1 analog developed by recombinant DNA technology are already available (e.g. Lirglutide, Albiglutide). They are similar (homologous) with human GLP-1 with modified pharmakokinetics. Some are for once a daily use and some are even for once a week use.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Pharmaceuticals
- Drugs